The Canadian journal of hospital pharmacy最新文献

{"title":"Medication Utilization at a Provincial Remand Centre.","authors":"Caitlin Olatunbosun, Kory Sloan, Laura Miskimins, Hazel Gabert, Rekha Jabbal, Catherine Biggs","doi":"10.4212/cjhp.3766","DOIUrl":"10.4212/cjhp.3766","url":null,"abstract":"<p><strong>Background: </strong>Evaluation of medication utilization highlights health needs and facilitates rational drug use in a population. Data on medication utilization in correctional facilities are limited.</p><p><strong>Objective: </strong>To describe the types and volumes of medications used at a provincial remand centre, by drug schedule and therapeutic classification.</p><p><strong>Methods: </strong>In this retrospective review of medications used at the Edmonton Remand Centre over a 1-year period (September 2022 to August 2023), the data were analyzed descriptively. Data were compared by sex and age using the unpaired 2-sided <i>t</i> test and by medication type using the χ² test.</p><p><strong>Results: </strong>Of 8772 persons admitted to the remand centre during the study period, 6296 (71.8%) had medication orders. Of these, 5446 (86.5%) had orders for over-the-counter medications, 5591 (88.8%) for prescription medications, and 2513 (39.9%) for narcotics. Patients 40 years of age or younger had proportionally more orders for narcotic medications. The therapeutic classes with the highest proportions of patients were those for treating mental health problems, substance use disorder, pain, constipation, and infectious diseases.</p><p><strong>Conclusions: </strong>Most patients in this corrections facility were receiving medications. Utilization trends specific to the corrections setting should be considered to support patient care.</p>","PeriodicalId":94225,"journal":{"name":"The Canadian journal of hospital pharmacy","volume":"78 3","pages":"e3766"},"PeriodicalIF":0.0,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12204709/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144532156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adoption of Closed-System Drug Transfer Devices: Effectiveness in Reducing Occupational Exposure to Hazardous Drugs and the Change Management Process.","authors":"Chun-Yip Hon, Jackie Ellis, Tina I En Chiang, Matty Jeronimo, Rita Ciconte, A Dana Ménard","doi":"10.4212/cjhp.3676","DOIUrl":"10.4212/cjhp.3676","url":null,"abstract":"<p><strong>Background: </strong>Closed-system drug transfer devices (CSTDs) are known to be effective in reducing hazardous drug contamination and, in turn, the risk of exposure for health care workers. In response, the Fraser Health Authority in British Columbia had plans to introduce CSTDs into practice.</p><p><strong>Objectives: </strong>To confirm the effectiveness of CSTDs in reducing hazardous drug contamination and to understand health care workers' perspectives regarding the change management process for CSTD implementation.</p><p><strong>Methods: </strong>Surface wipe samples were collected at 4 health care facilities within the health authority over 3 time points: T₀, 1 month before CSTDs were introduced; T₁, 1 month after CSTDs were introduced; and T₂, 5 months after implementation. Comparative analysis of drug contamination levels was conducted between 2 pairs of sampling times: T₀ vs T₁ and T₁ vs T₂. To understand the change management process, health care workers at the same departments (as those where wipe samples were collected) were surveyed.</p><p><strong>Results: </strong>A total of 156 wipe samples were collected, consisting of 13 samples at each of the 4 sites at each of the 3 time points. There was a statistically significant reduction (<i>p</i> < 0.01) in the sum of the mass of drug contaminants from T₀ to T₁ (25.82 vs 4.01 ng/cm²) and from T₁ to T₂ (4.01 vs 0.068 ng/cm²). About 50 individuals responded to each question of the survey, and respondents had generally positive comments regarding the transition to CSTDs. Nevertheless, suggestions for improvement included offering various forms of training (e.g., online video, hands-on sessions) and ensuring ongoing communication.</p><p><strong>Conclusions: </strong>CSTDs were confirmed to be effective in reducing surface contamination levels, and the change management process employed by the health authority appeared to be well received.</p>","PeriodicalId":94225,"journal":{"name":"The Canadian journal of hospital pharmacy","volume":"78 3","pages":"e3676"},"PeriodicalIF":0.0,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12204714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144532151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Acetylsalicylic Acid with Rivaroxaban or Alternative Anticoagulants for Thromboprophylaxis in Elective Total Hip Arthroplasty: A Retrospective Cohort Study.","authors":"Rebecca Norman, Jason Kielly, Kwadwo Osei Bonsu, Rufaro S Chitsike, Stephanie Young","doi":"10.4212/cjhp.3599","DOIUrl":"10.4212/cjhp.3599","url":null,"abstract":"<p><strong>Background: </strong>The role of acetylsalicylic acid (ASA) thromboprophylaxis following elective total hip arthroplasty (THA) remains unclear, given limited high-quality evidence and differing guideline recommendations.</p><p><strong>Objectives: </strong>To compare thromboprophylaxis prescribing patterns for ASA and alternative anticoagulants and to determine subsequent health care utilization for patients undergoing elective THA within one Canadian health region.</p><p><strong>Methods: </strong>This retrospective cohort study involved adult patients who underwent THA between January and June 2019, comparing those who received ASA with those who received an alternative anticoagulant. Data for drug- and patient-specific characteristics are reported as means and standard deviations for continuous variables and as percentages for categorical variables. Patient characteristics and treatments were compared using χ² and <i>t</i> tests. Multivariable logistic regression was conducted to identify predictors of the choice of treatment (ASA vs rivaroxaban).</p><p><strong>Results: </strong>Of the 180 patients who underwent THA in the study period, thromboprophylaxis consisted of ASA for 153 (85.0%) and rivaroxaban for 27 (15.0%). The most common ASA regimen was 325 mg daily (152/153, 99.3%) for a mean of 43.0 (standard deviation 6.9) days. Significant patient differences between the ASA and rivaroxaban groups included history of malignancy (6.5% vs 51.9%, <i>p</i> < 0.001), previous venous thromboembolism (0% vs 11.1%, <i>p</i> = 0.001), thrombophilia (0% vs 3.7%, <i>p</i> = 0.018), and chemotherapy (0% vs 11.1%, <i>p</i> < 0.001). Patients with a history of malignancy were more likely to receive rivaroxaban than ASA (odds ratio 31.65, 95% confidence interval 18.22 to 2.4 × 10⁴, <i>p</i> < 0.001). No differences were observed for health care utilization.</p><p><strong>Conclusions: </strong>ASA was used as thromboprophylaxis after THA for most patients within one Canadian health region. Significant differences in baseline characteristics were noted between patients who received ASA and those who received rivaroxaban.</p>","PeriodicalId":94225,"journal":{"name":"The Canadian journal of hospital pharmacy","volume":"78 3","pages":"e3599"},"PeriodicalIF":0.0,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12204713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144532152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Touche à tout.","authors":"Clarence Chant","doi":"10.4212/cjhp.3831","DOIUrl":"10.4212/cjhp.3831","url":null,"abstract":"","PeriodicalId":94225,"journal":{"name":"The Canadian journal of hospital pharmacy","volume":"78 2","pages":"e3831"},"PeriodicalIF":0.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12119094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144277181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strengthening Our Community.","authors":"Mary Gunther","doi":"10.4212/cjhp.3815","DOIUrl":"https://doi.org/10.4212/cjhp.3815","url":null,"abstract":"","PeriodicalId":94225,"journal":{"name":"The Canadian journal of hospital pharmacy","volume":"78 2","pages":"e3815"},"PeriodicalIF":0.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12119096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144277180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renforcer notre communauté.","authors":"Mary Gunther","doi":"10.4212/cjhp.3828","DOIUrl":"https://doi.org/10.4212/cjhp.3828","url":null,"abstract":"","PeriodicalId":94225,"journal":{"name":"The Canadian journal of hospital pharmacy","volume":"78 2","pages":"e3828"},"PeriodicalIF":0.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12119095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144277179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Buprenorphine/Naloxone in an Adult with Cystic Fibrosis.","authors":"Tamara Mihic, Nadia Fairbairn, Seonaid Nolan, Renée Dagenais, Bradley S Quon, M Eugenia Socias","doi":"10.4212/cjhp.3700","DOIUrl":"10.4212/cjhp.3700","url":null,"abstract":"","PeriodicalId":94225,"journal":{"name":"The Canadian journal of hospital pharmacy","volume":"78 2","pages":"e3700"},"PeriodicalIF":0.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12119097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144277182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Innovative Approach to Interdisciplinary Training: A Pharmacy Resident's Day with a Critical Care Nurse.","authors":"Lama H Nazer, Naheel Said, Wedad Awad, Asma Kharabsheh, Musab Smadi, Saad Jaddoua","doi":"10.4212/cjhp.3780","DOIUrl":"10.4212/cjhp.3780","url":null,"abstract":"","PeriodicalId":94225,"journal":{"name":"The Canadian journal of hospital pharmacy","volume":"78 2","pages":"e3780"},"PeriodicalIF":0.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12119093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144277177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Jack (and Jill) of All Trades.","authors":"Clarence Chant","doi":"10.4212/cjhp.3804","DOIUrl":"10.4212/cjhp.3804","url":null,"abstract":"","PeriodicalId":94225,"journal":{"name":"The Canadian journal of hospital pharmacy","volume":"78 2","pages":"e3804"},"PeriodicalIF":0.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12119092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144277178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Views of British Columbians Regarding the Environmental Impact of Medication Use.","authors":"Madison Lai, Karen Dahri, Gigi Wong, Michael Legal","doi":"10.4212/cjhp.3707","DOIUrl":"https://doi.org/10.4212/cjhp.3707","url":null,"abstract":"<p><strong>Background: </strong>Pharmaceuticals affect planetary health through environmental contamination from human excretions, improper drug disposal, and greenhouse gas emissions, derived from manufacturing as well as from use. Research suggests that patients will choose environmentally friendly options for minor ailments, but not severe conditions. To date, no Canadian research has explored patients' views on this topic.</p><p><strong>Objectives: </strong>To characterize the views of British Columbians regarding medication-related environmental sustainability and to determine how these views relate to medication decisions.</p><p><strong>Methods: </strong>A web-based survey was distributed across British Columbia from October 30, 2023, to February 29, 2024. Residents of British Columbia at least 18 years of age who could complete an online survey in English were eligible to participate. Descriptive statistics and thematic analysis were used.</p><p><strong>Results: </strong>A total of 255 responses were received. When presented with a scenario related to stroke, more than half of respondents (51%) preferred the medication with higher efficacy and greater environmental harm; in contrast, for scenarios involving the common cold and asthma, more than half chose the medication with lower efficacy and lower environmental harm (54% and 59%, respectively). When cost was introduced, only 54% stated they would choose the more environmentally friendly medication if it was more expensive, whereas 97% would do so if it was less expensive. Themes from open-ended questions focused on cost, manufacturer considerations, and education.</p><p><strong>Conclusions: </strong>Respondents were willing to choose the environmentally friendly medication for less serious conditions, but not for conditions perceived as life-threatening and/or debilitating. Cost may be a barrier to accessing environmentally friendly options. Public education opportunities may help to inform more sustainable choices. Additionally, there may be value in manufacturer regulations or policies to ensure that the environmental impact of medications is considered.</p>","PeriodicalId":94225,"journal":{"name":"The Canadian journal of hospital pharmacy","volume":"78 2","pages":"e3707"},"PeriodicalIF":0.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144083050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}